ALPS Advisors’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.3M | Sell |
41,380
-13,952
| -25% | -$437K | 0.01% | 443 |
|
|
2025
Q1 | $1.86M | Sell |
55,332
-6,316
| -10% | -$212K | 0.01% | 359 |
|
|
2024
Q4 | $2.42M | Buy |
61,648
+4,659
| +8% | +$183K | 0.02% | 319 |
|
|
2024
Q3 | $2.24M | Sell |
56,989
-1,864
| -3% | -$73.4K | 0.02% | 337 |
|
|
2024
Q2 | $2.29M | Buy |
58,853
+5,653
| +11% | +$220K | 0.02% | 317 |
|
|
2024
Q1 | $2.29M | Buy |
53,200
+2,420
| +5% | +$104K | 0.02% | 329 |
|
|
2023
Q4 | $2.34M | Buy |
50,780
+3,431
| +7% | +$158K | 0.02% | 313 |
|
|
2023
Q3 | $1.62M | Buy |
47,349
+626
| +1% | +$21.4K | 0.01% | 356 |
|
|
2023
Q2 | $1.8M | Buy |
46,723
+5,195
| +13% | +$200K | 0.02% | 331 |
|
|
2023
Q1 | $1.49M | Sell |
41,528
-843
| -2% | -$30.2K | 0.01% | 364 |
|
|
2022
Q4 | $1.67M | Buy |
42,371
+8,412
| +25% | +$332K | 0.01% | 336 |
|
|
2022
Q3 | $1.23M | Buy |
33,959
+2,461
| +8% | +$88.8K | 0.01% | 397 |
|
|
2022
Q2 | $958K | Buy |
+31,498
| New | +$958K | 0.01% | 486 |
|
|
2022
Q1 | – | Sell |
-59,702
| Closed | -$1.87M | – | 999 |
|
|
2021
Q4 | $1.87M | Buy |
59,702
+9,287
| +18% | +$290K | 0.02% | 296 |
|
|
2021
Q3 | $770K | Sell |
50,415
-3,544
| -7% | -$54.1K | 0.01% | 416 |
|
|
2021
Q2 | $1.01M | Sell |
53,959
-9,372
| -15% | -$175K | 0.01% | 400 |
|
|
2021
Q1 | $1.13M | Buy |
63,331
+77
| +0.1% | +$1.38K | 0.01% | 384 |
|
|
2020
Q4 | $973K | Buy |
63,254
+18,630
| +42% | +$287K | 0.01% | 392 |
|
|
2020
Q3 | $494K | Sell |
44,624
-3,080
| -6% | -$34.1K | 0.01% | 447 |
|
|
2020
Q2 | $598K | Buy |
+47,704
| New | +$598K | 0.01% | 425 |
|
|
2019
Q4 | – | Sell |
-51,356
| Closed | -$463K | – | 863 |
|
|
2019
Q3 | $463K | Sell |
51,356
-2,532
| -5% | -$22.8K | ﹤0.01% | 506 |
|
|
2019
Q2 | $531K | Sell |
53,888
-7,076
| -12% | -$69.7K | ﹤0.01% | 516 |
|
|
2019
Q1 | $619K | Buy |
60,964
+3,168
| +5% | +$32.2K | ﹤0.01% | 450 |
|
|
2018
Q4 | $365K | Buy |
+57,796
| New | +$365K | ﹤0.01% | 674 |
|